99% e-khata applications cleared: Greater Bengaluru Authority data

Bengaluru: Greater Bengaluru Authority's e-khata rollout has shown strong administrative performance, with over 99% ...
Ophthalmology Times

FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...
eLife

Separating selection from mutation in antibody language models

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...

Govt set to digitise land use change, mutation process

Lucknow: Making land-related administrative process simpler, the Yogi Adityanath govt is putting in efforts to introduce technology-based solutions.To provide a transparent ecosystem to residents who ...
The Hans India

Re-survey and mutation process via video conference reviewed

Kurnool: Joint Collector Noorul Qamar has directed the revenue machinery to complete the ongoing re-survey process in the district within the stipulated timeframe without any errors, while also ...
The New Indian Express

Karnataka revenue dept makes RRT software mandatory for all taluk-level mutation applications

BENGALURU: In a decisive push to plug revenue leak, the revenue department has made it mandatory for all taluk-level Rapid Revenue Team staff to register every mutation application exclusively through ...
Seeking Alpha

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for ...

PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass., Nov. 20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc ...
Nasdaq

Kura Oncology and Kyowa Kirin Announce FDA Acceptance of New Drug Application for Ziftomenib in Relapsed or Refractory AML with NPM1 Mutation

Kura Oncology and Kyowa Kirin announce FDA acceptance of ziftomenib NDA for relapsed/refractory AML, targeting a November 2025 decision. Kura Oncology and Kyowa Kirin announced that the FDA has ...